Paolo Zola, MD, Università degli Studi di Torino, Turin, Italy, highlights the importance of his randomized control trial (RCT) comparing the efficacy of intensive (systematic CT scans, pap smears, biomarkers) versus minimalist (performing diagnostic tests only upon symptom presentation) detection of relapse in patients treated for gynecological cancer. Should the minimalist approach be determined as more effective than the intensive approach, these results could provide substantial economic benefits and increase availability of diagnostic tests for those patients who are more likely to need them. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
